AR118619A1 - Anticuerpos de unión a pd-1 - Google Patents
Anticuerpos de unión a pd-1Info
- Publication number
- AR118619A1 AR118619A1 ARP200100982A ARP200100982A AR118619A1 AR 118619 A1 AR118619 A1 AR 118619A1 AR P200100982 A ARP200100982 A AR P200100982A AR P200100982 A ARP200100982 A AR P200100982A AR 118619 A1 AR118619 A1 AR 118619A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- binding
- neutralize
- antigen
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G01N33/574—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910286677 | 2019-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118619A1 true AR118619A1 (es) | 2021-10-20 |
Family
ID=72750942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100982A AR118619A1 (es) | 2019-04-10 | 2020-04-08 | Anticuerpos de unión a pd-1 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12466887B2 (enExample) |
| EP (1) | EP3931223A4 (enExample) |
| JP (1) | JP7641910B2 (enExample) |
| CN (2) | CN111808190B (enExample) |
| AR (1) | AR118619A1 (enExample) |
| WO (1) | WO2020207432A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115776898A (zh) * | 2020-07-07 | 2023-03-10 | 百奥泰生物制药股份有限公司 | 双特异性抗体及其应用 |
| CN121668303A (zh) * | 2020-10-11 | 2026-03-17 | 百奥泰生物制药股份有限公司 | 抗pd-1抗体在联合用药中的应用 |
| WO2025140324A1 (zh) * | 2023-12-26 | 2025-07-03 | 百奥泰生物制药股份有限公司 | 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途 |
| WO2025190251A1 (zh) * | 2024-03-12 | 2025-09-18 | 百奥泰生物制药股份有限公司 | 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途 |
| CN120919340A (zh) * | 2024-05-09 | 2025-11-11 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用 |
| CN121015902A (zh) * | 2024-05-27 | 2025-11-28 | 百奥泰生物制药股份有限公司 | 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途 |
| CN121754666A (zh) * | 2024-09-30 | 2026-03-31 | 百奥泰生物制药股份有限公司 | 一种抗pd-1抗体制剂及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699658B1 (en) * | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| KR101586617B1 (ko) * | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| AU2016333517B2 (en) | 2015-10-02 | 2023-09-07 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| WO2018181064A1 (ja) | 2017-03-27 | 2018-10-04 | 国立大学法人北海道大学 | Ｐｄ－ｌ１検出用抗ｐｄ－ｌ１抗体 |
| WO2018217227A1 (en) * | 2017-05-24 | 2018-11-29 | Immunomedics, Inc. | Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1 |
| CN108997499B (zh) | 2018-09-12 | 2020-07-31 | 首都医科大学附属北京胸科医院 | 一种抗人pd-l1抗体及其应用 |
-
2020
- 2020-04-08 AR ARP200100982A patent/AR118619A1/es unknown
- 2020-04-09 CN CN202010275368.4A patent/CN111808190B/zh active Active
- 2020-04-09 WO PCT/CN2020/083954 patent/WO2020207432A1/en not_active Ceased
- 2020-04-09 EP EP20788554.2A patent/EP3931223A4/en active Pending
- 2020-04-09 US US17/602,715 patent/US12466887B2/en active Active
- 2020-04-09 JP JP2021560586A patent/JP7641910B2/ja active Active
- 2020-04-09 CN CN202311534081.9A patent/CN117603355A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111808190B (zh) | 2023-12-12 |
| US12466887B2 (en) | 2025-11-11 |
| EP3931223A1 (en) | 2022-01-05 |
| JP2022538375A (ja) | 2022-09-02 |
| US20220204623A1 (en) | 2022-06-30 |
| CN111808190A (zh) | 2020-10-23 |
| WO2020207432A1 (en) | 2020-10-15 |
| JP7641910B2 (ja) | 2025-03-07 |
| CN117603355A (zh) | 2024-02-27 |
| EP3931223A4 (en) | 2023-07-12 |
| TW202104262A (zh) | 2021-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110979A1 (es) | Moléculas de unión a cd70 y métodos de uso de las mismas | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| CY1122020T1 (el) | Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3 | |
| CY1119964T1 (el) | Αναστολεις οδου σηματοδοτησης notch και χρηση αυτων στη θεραπευτικη αγωγη καρκινων | |
| CO2018006299A2 (es) | Compuestos novedosos | |
| MY191649A (en) | Antibodies to tigit | |
| CR20160599A (es) | Diacuerpos Enlazados Covalentemente que tienen Inmunoreactividad con PD-1 y LAG-3, y Métodos de Uso de los Mismos | |
| SA523440043B1 (ar) | أجسام مضادة ضد cd3 إبسيلون جديدة | |
| CY1124456T1 (el) | Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων | |
| BR112018015754A2 (pt) | anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1 | |
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| EA201790465A1 (ru) | Антитела, композиции и применение | |
| EA201792307A1 (ru) | Способы репарации и регенерации тканей | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| NZ755083A (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis | |
| EP4442270A3 (en) | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof | |
| EA201491214A1 (ru) | Композиции и способы применения антител, нацеленных на фактор p | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
| EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| AR106307A1 (es) | Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular |